Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A basket study in selected solid tumors
2021-001009-56Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vibostolimab + pembrolizumab, vibostolimab, pembrolizumab and lenvatinib in Nonhematologic neoplasms and Cervical Cancer (CC) (3 arms), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Jun 2021; status: active.
02
Drugs
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)
Beyond the preview
Go deeper on 2021-001009-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001009-56.